Immune pathogenesis and immune therapy of a sclerosing variant of vulvar lichen sclerosus: a prospective cohort study

Background. Today, no unified clinical classification of vulvar lichen sclerosus is registered (is yet to be registered?). Isolation of pathogenetically and clinically different variants of its course enable new approaches to the treatment to be developed. Objective. To develop a pathogenetic therapy for the sclerosing variant of vulvar lichen sclerosus, taking into account its clinical and immunological characteristics. Methods. A prospective cohort study was conducted from 2018 to 2022 on the basis of Regional Clinical Hospital No. 2, Krasonodar, Russia. 292 patients aged 20 to 70 years were histologically diagnosed with vulvar lichen sclerosus. After a clinical examination using the scale for assessing subjective and objective clinical signs of vulvar lichen sclerosus, 154 patients with a sclerosing variant of the disease course were selected for the study. The control cohort consisted of 30 women of the same age category without vulvar lichen sclerosus, taking into account the exclusion criteria. The study involved a clinical assessment (in points) of objective and subjective criteria characteristic of this variant of vulvar lichen sclerosus, as well as an assessment of the level of cytokines (interleukin-20; interleukin-23; interleukin-10; tumor necrosis factor α, interferon γ) in peripheral blood of the patients from the main and control groups. One month after the immunotherapy with sodium deoxyribonucleate, the authors evaluated its clinical efficacy (using Numerical rating scale for pain (vulvodynia) and Vulvar pruritus severity scale) and immunological efficacy (repeated assessment of the level of the studied cytokines). Analysis and statistical processing of the obtained data were performed using Graph Pad Prism version 6.0 (GraphPad Software, Inc., San Diego, CA). Results. Depigmentation of the vulvar skin against the background of vulvar sclerosis and thickening features a sclerosing variant of vulvar lichen sclerosus compared to vulvar atrophy. Stenosis of the vaginal vestibule is either absent (51.3%) or predominantly corresponds to grade I, and is less specific than depigmentation and even skin atrophy. The subjective signs include a severe vulvar pruritus without or with moderately expressed (in 68.1%) vulvodynia. An immunological study showed a statistically significant increase in the level of interleukin-20 (p < 0.0001), interleukin-23 (p < 0.0001), interferon-γ (p < 0.03), tumor necrosis factor α (p < 0.009) in patients with maximal tissue sclerosis with respect to the control group, along with a statistically significant decrease in the level of anti-inflammatory interleukin-10 (p < 0.01). The immunological efficacy of sodium deoxyribonucleate was confirmed by a statistically significant (compared to baseline) decrease in interleukin-20 (p < 0.0001), interferon-γ and tumor necrosis factor α (p < 0.002), interleukin-23 (p < 0.012) without statistical differences with the control group (except for interleukin-23, the level of which decreased after therapy but remained statistically higher (p < 0.01) than in the control group). Clinical efficacy of immunotherapy was confirmed by a statistically significant (p < 0.001) reduction in vulvodynia and vulvar pruritus after the treatment. Conclusion. The obtained data demonstrate characteristic clinical features and immunological differences in relation to the norm in women with the sclerosing variant of vulvar lichen sclerosus, thereby justifying the use of sodium deoxyribonucleate in this variant with confirmed clinical and immunological efficacy.

1. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, Mohd Mustapa MF, Exton LS. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178(4):839–853. https://doi.org/10.1111/bjd.16241

2. Vittrup G, Mørup L, Heilesen T, Jensen D, Westmark S, Melgaard D. Quality of life and sexuality in women with lichen sclerosus: a cross-sectional study. Clin Exp Dermatol. 2022;47(2):343–350. https://doi.org/10.1111/ced.14893

3. Solopova AG, Achkasov EE, Makatsariya AD, Moskvichyova VS, Ivanov AE. Psycho-emotional profile of patients with vulvar lichen sclerosus. Obstetrics, Gynecology and Reproduction. 2020;14(2):203–210 (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.106

4. Pérez-López FR, Vieira-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017;20(4):339–347. https://doi.org/10.1080/13697137.2017.1343295

5. Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci. 2019;15(7):1429–1439. https://doi.org/10.7150/ijbs.34613

6. Campanati A, Martina E, Offidani A. The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going. Biomedicines. 2022;10(5):950. https://doi.org/10.3390/biomedicines10050950

7. Oyama N, Hasegawa M. Lichen Sclerosus: A Current Landscape of Autoimmune and Genetic Interplay. Diagnostics (Basel). 2022;12(12):3070. https://doi.org/10.3390/diagnostics12123070

8. Marfatia Y, Surani A, Baxi R. Genital lichen sclerosus et atrophicus in females: An update. Indian J Sex Transm Dis AIDS. 2019;40(1):6–12. https://doi.org/10.4103/ijstd.IJSTD_23_19

9. Haefner HK, Welch KC, Rolston AM, Koeppe ES, Stoffel EM, Kiel MJ, Berger MB. Genomic Profiling of Vulvar Lichen Sclerosus Patients Shows Possible Pathogenetic Disease Mechanisms. J Low Genit Tract Dis. 2019;23(3):214–219. https://doi.org/10.1097/LGT.0000000000000482

10. Guarneri F, Giuffrida R, Di Bari F, Cannavò SP, Benvenga S. Thyroid Autoimmunity and Lichen. Front Endocrinol (Lausanne). 2017;8:146. https://doi.org/10.3389/fendo.2017.00146

11. van der Meijden WI, Boffa MJ, Ter Harmsel WA, Kirtschig G, Lewis FM, Moyal-Barracco M, Tiplica GS, Sherrard J. 2016 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2017;31(6):925–941. https://doi.org/10.1111/jdv.14096

12. Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar Lichen Sclerosus: Current Perspectives. Int J Womens Health. 2020;12:11–20. https://doi.org/10.2147/IJWH.S191200

13. Doulaveri G, Armira K, Kouris A, Karypidis D, Potouridou I. Genital vulvar lichen sclerosus in monozygotic twin women: a case report and review of the literature. Case Rep Dermatol. 2013;5(3):321–325. https://doi.org/10.1159/000356775

14. Magro CM, Kalomeris TA, Mo JH, Rice M, Nuovo G. Lichen sclerosus: A C5B-9 mediated chronic microvascular injury syndrome potentially reflective of common adult comorbidities. Ann Diagn Pathol. 2023;63:152098. https://doi.org/10.1016/j.anndiagpath.2022.152098

15. Khan Mohammad Beigi P. The Immunogenetics of Morphea and Lichen Sclerosus. Adv Exp Med Biol. 2022;1367:155–172. https://doi.org/10.1007/978-3-030-92616-8_7

16. Terlou A, Santegoets LA, van der Meijden WI, Heijmans-Antonissen C, Swagemakers SM, van der Spek PJ, Ewing PC, van Beurden M, Helmerhorst TJ, Blok LJ. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. J Invest Dermatol. 2012;132(3 Pt 1):658–666. https://doi.org/10.1038/jid.2011.369

17. Zharov AV, Kolesnikova EV, Penzhoyan GA, Anikina GA. Variants of the clinical course of sclerotic external genitalia in women. Russian Bulletin of Obstetrician-Gynecologist. 2022;22(5):92–99 (In Russ.). https://doi.org/10.17116/rosakush20222205192

18. Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines--from host defence to tissue homeostasis. Nat Rev Immunol. 2014;14(12):783–795. https://doi.org/10.1038/nri3766

19. Hanakawa S, Kitoh A, Shibuya R, Dainichi T, Nomura T, Honda T, Egawa G, Otsuka A, Nakajima S, Fujita M, Kabashima K. Percutaneous sensitization is limited by in situ inhibition of cutaneous dendritic cell migration through skin-resident regulatory T cells. J Allergy Clin Immunol. 2019;144(5):1343–1353.e8. https://doi.org/10.1016/j.jaci.2019.05.033

20. Xu X, Prens E, Florencia E, Leenen P, Boon L, Asmawidjaja P, Mus AM, Lubberts E. Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. Front Immunol. 2021;12:719562. https://doi.org/10.3389/fimmu.2021.719562

21. Yoon J, Leyva-Castillo JM, Wang G, Galand C, Oyoshi MK, Kumar L, Hoff S, He R, Chervonsky A, Oppenheim JJ, Kuchroo VK, van den Brink MR, Malefyt Rde W, Tessier PA, Fuhlbrigge R, Rosenstiel P, Terhorst C, Murphy G, Geha RS. IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization. J Exp Med. 2016;213(10):2147–2166. https://doi.org/10.1084/jem.20150376

22. Wang P, Chan WK, Wang J, Yang Z, Wang Y. Role of IL-22 in intestinal microenvironment and potential targeted therapy through diet. Immunol Res. 2023;71(2):121–129. https://doi.org/10.1007/s12026-022-09325-5

23. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med. 2006;6(1):13–19. https://doi.org/10.1007/s10238-006-0088-5. PMID: 16550339

24. Fröhlich E, Wahl R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol. 2017;8:521. https://doi.org/10.3389/fimmu.2017.00521

25. Fedorenko TV, Kolesnikova NV, Pashkova IA. Early cytokine predictors of acute kidney transplant rejection. Russian Journal of Immunology. 2019;13(22):590–592 (In Russ.). https://doi.org/10.31857/S102872210006984-7

26. Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian YW, Bivi N, Mack JK, Siegel RW, Nickoloff BJ. Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay. Sci Rep. 2019;9(1):5211. https://doi.org/10.1038/s41598-019-41609-z

27. Patrushev AV, Samtsov AV, Soukharev AV. Features of the cytokine profile and the effectiveness of radical treatment of focal infection in patients with psoriasis. Vestnik Dermatologii i Venerologii. 2021;97(2):32–40 (In Russ.). https://doi.org/10.25208/vdv1200

28. Euasobhon P, Atisook R, Bumrungchatudom K, Zinboonyahgoon N, Saisavoey N, Jensen MP. Reliability and responsivity of pain intensity scales in individuals with chronic pain. Pain. 2022;163(12):e1184–e1191. https://doi.org/10.1097/j.pain.0000000000002692

29. Kolesnikova EV, Zharov AV, Penzhoyan GA, Mingaleva NV. Management of patients with the atrophic variant of vulvar lichen sclerosus. Gynecology. 2022;24(5):362–368 (In Russ.). https://doi.org/10.26442/20795696.2022.5.201898

30. Mashayekhi S, Flohr C, Lewis FM. The treatment of vulval lichen sclerosus in prepubertal girls: a critically appraised topic. Br J Dermatol. 2017;176(2):307–316. https://doi.org/10.1111/bjd.15202

31. Rusinova TV, Chudilova GA, Kolesnikova NV. Comparative analysis immunotropic effects in vitro derinat and synthetic tlr9 agonist on receptor function of neutrophilic granulocytes and monocytes in normal and infectious process. Kuban Scientific Medical Bulletin. 2016;(5):94–97 (In Russ.). https://doi.org/10.25207/1608-6228-2016-5-94-97

32. Nosik DN, Kalnina LB, Lobach OA, Chataeva MS, Berezhnaya EV, Bochkova MS, Kiseleva IA, Selimova LM, Nosik NN. Antiviral and virucidal activity of sodium deoxyribonucleate and its complex with iron against viruses of different kingdoms and families. Vopr Virusol. 2023;67(6):506–515 (In Russ.). https://doi.org/10.36233/0507-4088-148

33. Hsu WL, Lu JH, Noda M, Wu CY, Liu JD, Sakakibara M, Tsai MH, Yu HS, Lin MW, Huang YB, Yan SJ, Yoshioka T. Derinat Protects Skin against Ultraviolet-B (UVB)-Induced Cellular Damage. Molecules. 2015;20(11):20297–20311. https://doi.org/10.3390/molecules201119693

34. Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. https://doi.org/10.1038/s41419-022-04523-3

35. Kang SY, Um JY, Chung BY, Lee SY, Park JS, Kim JC, Park CW, Kim HO. Moisturizer in Patients with Inflammatory Skin Diseases. Medicina (Kaunas). 2022;58(7):888. https://doi.org/10.3390/medicina58070888

36. Sokolova AV, Apolikhina IA, Zaitsev NV, Chernukha LV. Clinical and morphological stages vulvar lichen sclerosus. Gynecology. 2020;22(4):22–27 (In Russ.). https://doi.org/10.26442/20795696.2020.4.200278